Descripción del proyecto
Tecnología de chip para el cultivo «in vitro» de órganos vascularizados en miniatura
La investigación y el desarrollo de fármacos dependen en gran medida de modelos animales, pero su fisiología y biología dispares pueden dificultar la interpretación de los resultados. Los modelos celulares «in vitro» son demasiado simples y no reflejan la fisiología de los tejidos, lo que pone de manifiesto la necesidad de mejores modelos. En el proyecto OrganoPlate Graft, financiado con fondos europeos, se desarrollará el primer método de cultivo «in vitro» de alto rendimiento para tejidos vascularizados. Los científicos del proyecto emplearán una tecnología de órgano en un chip desarrollada previamente, para cultivar y supervisar de forma controlada órganos tridimensionales en miniatura «in vitro». La puesta en práctica de este sistema favorecerá el diseño de experimentos novedosos en investigación y desarrollo, así como en el ámbito clínico.
Objetivo
PROBLEM – The drug development cycle, from basic research to testing efficacy, toxicity, and safety of new therapeutics, is largely depending on animal models. However animal biology and pathology differ from human biology at crucial points. The sector is aware of the significant complications in their usage, but lacks better alternatives. Highly advanced technology exists for the culture of cell systems, organs, tumors, etc. outside the body (‘in vitro’). However, the existing culture models lack functional blood vessels – a vital structure inside the body (‘in vivo’). There is a great unmet need for better models of human biology, to speed up both basic research on human biology as well as the development of novel, much needed therapeutic solutions. SOLUTION – OrganoPlate Graft involves the development to market readiness of the first high-throughput in vitro culture method for vascularized tissue that is unrivalled by the available in vitro options. An extensive proof of concept (PoC) for this method has been obtained. The new product will be launched within 6-months post-project and, for the first time, allow for the study and manipulation of human tissues with functional human vascularization. COMPANY – Founded in 2013, the Dutch SME MIMETAS was the first party to commercially exploit organ-on-a-chip technology that enables accurately controlled and monitored in vitro cultivation 3D ‘mini-organs’. MIMETAS currently employs > 60 professionals, generates year-on year multi-million revenues, and is projected to be profitable as of 2020. RESULTS – The results of the 2-year OrganoPlate Graft project will empower Users by aiding them to grow tissues with human vascularization in vitro – enabling the replacement of a wealth of animal experiments and the design of completely novel experiments in research, development and clinical settings. OrganoPlate Graft will cost €3M, employ 10 new FTEs, and is projected to add 40 FTE and >€50M annual revenues to MIMETAS by 2022.
Ámbito científico
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEInst-2018-2020-2
Régimen de financiación
SME-2 - SME instrument phase 2Coordinador
2342 DH Oegstgeest
Países Bajos
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.